Zhong Guo Jing Ji Wang·2025-08-13 03:29Core Viewpoint - Fudan Zhangjiang (688505.SH) reported a decline in revenue and net profit for the first half of 2025, indicating significant financial challenges faced by the company [1][2]. Financial Performance Summary - For the first half of 2025, the company achieved operating revenue of 390.83 million yuan, a decrease of 4.42% compared to the same period last year [1][2]. - The net profit attributable to shareholders was 5.72 million yuan, down 91.89% year-on-year [1][2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -9.49 million yuan, compared to 43.68 million yuan in the previous year, reflecting a decline of 121.73% [1][2]. - The net cash flow from operating activities was 62.21 million yuan, showing a significant increase of 125% year-on-year [1][2]. Historical Financial Data - From 2021 to 2024, the company's operating revenue showed a downward trend: 1.14 billion yuan in 2021, 1.03 billion yuan in 2022, 851 million yuan in 2023, and 709 million yuan in 2024 [2]. - The net profit attributable to shareholders also decreased during the same period: 213 million yuan in 2021, 138 million yuan in 2022, 109 million yuan in 2023, and 40 million yuan in 2024 [2]. - The net cash flow from operating activities fluctuated, with a negative cash flow of -17 million yuan in 2024, compared to positive cash flows in previous years [2]. Fundraising and Use of Proceeds - Fudan Zhangjiang raised a total of 1.074 billion yuan, with a net amount of 974.32 million yuan after deducting issuance costs [4]. - The company planned to use the raised funds for the registration project of Hematopoietic Stem Cell Transplantation in the U.S., continuous development of biopharmaceutical innovation, and acquisition of minority equity in Taizhou Fudan Zhangjiang [4].